Stephen Falk

25.0k total citations · 5 hit papers
123 papers, 11.4k citations indexed

About

Stephen Falk is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Stephen Falk has authored 123 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Pulmonary and Respiratory Medicine, 66 papers in Oncology and 52 papers in Surgery. Recurrent topics in Stephen Falk's work include Gastric Cancer Management and Outcomes (51 papers), Esophageal Cancer Research and Treatment (38 papers) and Colorectal Cancer Treatments and Studies (30 papers). Stephen Falk is often cited by papers focused on Gastric Cancer Management and Outcomes (51 papers), Esophageal Cancer Research and Treatment (38 papers) and Colorectal Cancer Treatments and Studies (30 papers). Stephen Falk collaborates with scholars based in United Kingdom, United States and Germany. Stephen Falk's co-authors include David Cunningham, Timothy Iveson, David B. Smith, Ruth E. Langley, Sally Stenning, F. Lofts, William Allum, M. Nicolson, Cornelis J.�H. van de Velde and J.H. Scarffe and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Stephen Falk

121 papers receiving 11.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

2006 4.5k citations David Cunningham, William Allum et al. profile →
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer

2009 602 citations David Cunningham, Ian Chau et al. Journal of Clinical Oncology profile →
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

2013 547 citations Ian Chau, David Cunningham et al. The Lancet Oncology profile →
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

2013 459 citations David Cunningham, Tim Maughan et al. The Lancet Oncology profile →
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

2013 405 citations John Bridgewater, Fareeda Y. Coxon et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stephen Falk United Kingdom	38	7.7k	5.6k	4.9k	2.1k	870	123	11.4k
M. Nicolson United Kingdom	38	7.9k 1.0×	4.2k 0.7×	4.5k 0.9×	2.3k 1.1×	616 0.7×	112	10.8k
Narikazu Boku Japan	61	10.0k 1.3×	6.3k 1.1×	8.1k 1.7×	3.1k 1.5×	1000 1.1×	541	15.3k
William Allum United Kingdom	37	9.4k 1.2×	6.8k 1.2×	3.2k 0.7×	3.5k 1.6×	730 0.8×	140	12.2k
Ruth E. Langley United Kingdom	30	6.5k 0.8×	4.2k 0.8×	2.8k 0.6×	1.9k 0.9×	755 0.9×	104	9.0k
H. Wilke Germany	41	5.9k 0.8×	3.7k 0.7×	3.7k 0.8×	1.3k 0.6×	392 0.5×	142	8.3k
David B. Smith United Kingdom	23	4.7k 0.6×	3.1k 0.6×	3.0k 0.6×	1.6k 0.7×	680 0.8×	58	7.4k
Thierry Conroy France	42	4.2k 0.5×	5.0k 0.9×	6.1k 1.2×	773 0.4×	984 1.1×	147	9.7k
Giuseppe Aprile Italy	38	5.0k 0.7×	2.5k 0.4×	5.6k 1.1×	1.3k 0.6×	1.3k 1.5×	232	9.8k
Timothy Iveson United Kingdom	35	10.3k 1.3×	8.4k 1.5×	9.2k 1.9×	2.7k 1.3×	1.1k 1.3×	117	17.1k
Yelena Y. Janjigian United States	48	5.0k 0.7×	2.4k 0.4×	5.0k 1.0×	1.1k 0.5×	1.1k 1.2×	253	8.5k

Countries citing papers authored by Stephen Falk

Since Specialization

Citations

This map shows the geographic impact of Stephen Falk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Falk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Falk more than expected).

Fields of papers citing papers by Stephen Falk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen Falk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Falk. The network helps show where Stephen Falk may publish in the future.

Co-authorship network of co-authors of Stephen Falk

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen Falk. A scholar is included among the top collaborators of Stephen Falk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen Falk. Stephen Falk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Halperin, Daniel M., Sten Myrehaug, Pamela L. Kunz, et al.. (2024). 211MO First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study. Annals of Oncology. 35. S92–S93. 4 indexed citations

Adams, Richard, Ewan Brown, Louise Brown, et al.. (2017). Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial. The Lancet. Gastroenterology & hepatology. 3(3). 162–171. 37 indexed citations

Metcalfe, Chris, Kerry Avery, Richard Berrisford, et al.. (2016). Comparing open and minimally invasive surgical procedures for oesophagectomy in the treatment of cancer: the ROMIO (Randomised Oesophagectomy: Minimally Invasive or Open) feasibility study and pilot trial. Health Technology Assessment. 20(48). 1–68. 33 indexed citations

Foster, Jake, Paul Ewings, Stephen Falk, et al.. (2016). Surgical timing after chemoradiotherapy for rectal cancer, analysis of technique (STARRCAT): results of a feasibility multi-centre randomized controlled trial. Techniques in Coloproctology. 20(10). 683–693. 17 indexed citations

Neoptolemos, John P., Paula Ghaneh, Juan W. Valle, et al.. (2016). ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 34(15_suppl). LBA4006–LBA4006. 4 indexed citations

Hurt, Chris, John Bridgewater, Stephen Falk, et al.. (2016). O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC). Annals of Oncology. 27. ii118–ii118. 6 indexed citations

Blazeby, Jane, Sean Strong, Jenny Donovan, et al.. (2014). Feasibility RCT of definitive chemoradiotherapy or chemotherapy and surgery for oesophageal squamous cell cancer. British Journal of Cancer. 111(2). 234–240. 27 indexed citations

Blencowe, Natalie, Robert N. Whistance, Daniel Stevens, et al.. (2014). Outcome Reporting in Neoadjuvant Surgical Trials: A Systematic Review of the Literature and Proposals for New Standards. JNCI Journal of the National Cancer Institute. 106(9). dju217–dju217. 10 indexed citations

Crosby, T., Chris Hurt, Stephen Falk, et al.. (2013). Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. The Lancet Oncology. 14(7). 627–637. 272 indexed citations

10.

Smyth, Elizabeth, Ruth E. Langley, Sally Stenning, et al.. (2013). ST03: A randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, esophagogastric junction (OGJ), or lower esophageal adenocarcinoma.. Journal of Clinical Oncology. 31(15_suppl). TPS4156–TPS4156. 1 indexed citations

11.

Lowry, Lisa, Paul Smith, Wendi Qian, et al.. (2011). Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. Radiotherapy and Oncology. 100(1). 86–92. 247 indexed citations

12.

Hatton, M., Matthew Nankivell, Stephen Falk, et al.. (2010). Induction Chemotherapy and Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Patients With Locally Advanced Inoperable Non–Small-Cell Lung Cancer: The MRC INCH Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. 81(3). 712–718. 26 indexed citations

13.

Falk, Stephen & Chris Williams. (2009). Lung Cancer. 1 indexed citations

14.

Cunningham, David, Ian Chau, Deborah Stocken, et al.. (2009). Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology. 27(33). 5513–5518. 602 indexed citations breakdown →

15.

Din, Omar, J.F. Lester, Alison Cameron, et al.. (2008). Routine Use of Continuous, Hyperfractionated, Accelerated Radiotherapy for Non–Small-Cell Lung Cancer: A Five-Center Experience. International Journal of Radiation Oncology*Biology*Physics. 72(3). 716–722. 14 indexed citations

16.

McNair, Angus, Chris Metcalfe, C P Barham, et al.. (2008). Maximising recruitment into randomised controlled trials: The role of multidisciplinary cancer teams. European Journal of Cancer. 44(17). 2623–2626. 44 indexed citations

17.

Ruff, Paul, Bernardo L. Rapoport, Stephen Falk, et al.. (2004). Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer. 4(1). 36–36. 8 indexed citations

18.

Lightman, Stafford L., Stephen Falk, Vidya Mohamed‐Ali, et al.. (2002). What is the role of the insulin‐like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated?. Clinical Endocrinology. 56(6). 723–733. 47 indexed citations

19.

Cunningham, David, Stephen Falk, & D Jackson. (2002). Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer. British Journal of Cancer. 86(11). 1677–1683. 26 indexed citations

20.

Falk, Stephen & Paul J. Smith. (1992). DNA Damaging and Cell Cycle Effects of the Topoisomerase I Poison Camptothecin in Irradiated Human Cells. International Journal of Radiation Biology. 61(6). 749–757. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact